AnaptysBio Q3 EPS $(1.41) Beats $(1.79) Estimate, Sales $3.32M Beat $2.51M Estimate
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio reported Q3 earnings per share (EPS) of $(1.41), beating the analyst consensus estimate of $(1.79) by 21.23%. This is a 19.49% decrease from the same period last year. The company also reported quarterly sales of $3.32M, beating the analyst consensus estimate of $2.51M by 32.19%. This is a 156.61% increase from the same period last year.
November 02, 2023 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AnaptysBio's Q3 earnings and sales beat analyst estimates, which could positively impact the stock in the short term.
AnaptysBio reported better than expected Q3 earnings and sales, which is generally seen as positive news by investors and could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100